|  | Primary cohort subgroups | Failed prophylactic treatments at TT | Botox | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
G43, primary cohort | Prophylactic | Acute | No prescription | p | 0 | 1 | 2 | ≥3 | p | |||
Follow-up time, median (min-max) | 2.84 (0.09–6.00) | 3.21 (0.11–6.00) | 2.49 (0.09–6.00) | 3.05 (0.09–6.00) | < 0.001 | 2.78 (0.09–6.00) | 3.09 (0.11–6.00) | 3.79 (0.13–6.00) | 4.28 (0.36–6.00) | < 0.001 | 2.83 (0.09–6.00) | |
N | 17,623 | 2199 | 6525 | 8899 | < 0.001 | 15,424 | 1767 | 334 | 98 | < 0.001 | 53 | |
Female, % | 78.9% | 81.7% | 80.5% | 77.0% | < 0.001 | 78.5% | 81.1% | 84.4% | 83.7% | 0.002 | 83.0% | |
Age, mean | 39 (15–77) | 41 (15–70) | 38 (15–77) | 38 (15–75) | < 0.001 | 38 (15–77) | 41 (15–70) | 41 (17–68) | 41 (21–61) | < 0.001 | 39 (20–68) | |
Prohpylactic prescription, n (%) | 2199 (12.5) | 2199 (100) | – | – |  | – | 1767 (100) | 334 (100) | 98 (100) |  | 53 (100) | |
Acute prescription only, n (%) | 6525 (37) | – | 6525 (100) | – |  | 6525 (42.3) | – | – | – |  | – | |
No prescription, n (%) | 8899 (50.5) | – | – | 8899 (100) |  | 8899 (57.7) | – | – | – |  | – | |
Prophylactic treatment lines | 0, n (%) | 15,424 (87.5) | – | 6525 (100) | 8899 (100) |  | 15,424 (100) | – | – | – |  | – |
1st, n (%) | 1767 (10.0) | 1767 (80.4) | – | – |  | – | 1767 (100) | – | – |  | 14 (26.4) | |
2nd, n (%) | 334 (1.9) | 334 (15.2) | – | – |  | – | – | 334 (100) | – |  | 18 (34.0) | |
3rd, n (%) | 98 (0.6) | 98 (4.5) | – | – |  | – | – | – | 98 (100) |  | 21 (39.6) | |
Botulinum toxin A, n (%) | 53 (0.3) | 53 (0.3) | – | – |  | – | – | – | – |  | 53 (100) |